STOCK TITAN

ADMA Biologics (ADMA) director adds 12,500 shares in open-market buy

Filing Impact
(Moderate)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

ADMA Biologics director Jerrold B. Grossman bought 12,500 shares of common stock in an open-market transaction at $8.01 per share. Following this purchase, his directly owned stake shown in the filing increased to 501,384 shares of ADMA common stock.

The filing also lists additional ADMA shares held indirectly through Brookwood LLC, the Jerrold Grossman 2019 Irrevocable Trust, Genesis Foundation Inc., and his wife, reflecting interests associated with the director beyond his direct holdings.

Positive

  • None.

Negative

  • None.
Insider Grossman Jerrold B
Role null
Bought 12,500 shs ($100K)
Type Security Shares Price Value
Purchase Common Stock 12,500 $8.01 $100K
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 501,384 shares (Direct, null); Common Stock — 22,857 shares (Indirect, See footnote)
Footnotes (1)
  1. Represents an open market purchase in a single transaction. Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; and (ii) 490,694 shares of common stock owned by the reporting person. These shares are owned by Brookwood LLC ("Brookwood"). The Reporting Person is the managing member of Brookwood. These shares are owned by the Jerrold Grossman 2019 Irrevocable Trust, of which Dr. Grossman serves as investment trustee. These shares are owned by Genesis Foundation Inc. ("Genesis"). The Reporting Person is the President of Genesis. These shares are owned by the Reporting Person's wife.
Shares purchased 12,500 shares Open-market buy of ADMA common stock
Purchase price $8.01 per share Price for the 12,500-share transaction
Direct holdings after trade 501,384 shares Common stock directly owned after purchase
RSUs granted 10,690 RSUs Granted February 9, 2026, vesting February 9, 2027
Brookwood LLC holdings 175 shares Common stock owned by Brookwood LLC
Irrevocable Trust holdings 38,294 shares Common stock held by 2019 Irrevocable Trust
Genesis Foundation holdings 31,381 shares Common stock owned by Genesis Foundation Inc.
Spouse holdings 22,857 shares Common stock owned by reporting person’s wife
open market purchase financial
"Represents an open market purchase in a single transaction."
An open market purchase is when a company buys its own shares on public stock exchanges the same way any investor would, rather than through a private deal. Investors care because these purchases reduce the number of shares available, can boost earnings per share and share price, signal that management thinks the stock is undervalued, and use company cash that might otherwise go to reinvestment or dividends — like a business quietly buying back its own tickets at the box office.
RSUs financial
"Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest..."
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
Irrevocable Trust financial
"These shares are owned by the Jerrold Grossman 2019 Irrevocable Trust, of which Dr. Grossman serves as investment trustee."
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
Brookwood LLC financial
"These shares are owned by Brookwood LLC ("Brookwood"). The Reporting Person is the managing member of Brookwood."
Genesis Foundation Inc. financial
"These shares are owned by Genesis Foundation Inc. ("Genesis"). The Reporting Person is the President of Genesis."
indirect ownership financial
"Common Stock entries with ownership_type "indirect" and nature_of_ownership "See footnote"."
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Grossman Jerrold B

(Last)(First)(Middle)
C/O ADMA BIOLOGICS, INC.
465 STATE ROUTE 17

(Street)
RAMSEY NEW JERSEY 07446

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/11/2026P12,500A$8.01501,384(1)(2)D
Common Stock22,857ISee footnote(3)
Common Stock31,381ISee footnote(4)
Common Stock38,294ISee footnote(5)
Common Stock175ISee footnote(6)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents an open market purchase in a single transaction.
2. Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; and (ii) 490,694 shares of common stock owned by the reporting person.
3. These shares are owned by Brookwood LLC ("Brookwood"). The Reporting Person is the managing member of Brookwood.
4. These shares are owned by the Jerrold Grossman 2019 Irrevocable Trust, of which Dr. Grossman serves as investment trustee.
5. These shares are owned by Genesis Foundation Inc. ("Genesis"). The Reporting Person is the President of Genesis.
6. These shares are owned by the Reporting Person's wife.
/s/ Dr. Jerrold B. Grossman, by Adam S. Grossman as Attorney-in-fact05/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ADMA (ADMA) director Jerrold Grossman report?

Director Jerrold B. Grossman reported an open-market purchase of 12,500 shares of ADMA Biologics common stock. The shares were bought at $8.01 per share, increasing his directly held position as reflected in this Form 4 filing.

At what price did Jerrold Grossman buy ADMA (ADMA) shares?

He purchased ADMA Biologics common stock at $8.01 per share in an open-market transaction. This price applies to the entire 12,500-share purchase disclosed in the Form 4 insider trading report.

How many ADMA (ADMA) shares does Jerrold Grossman hold directly after this trade?

After the reported purchase, Jerrold B. Grossman directly holds 501,384 shares of ADMA Biologics common stock. This figure reflects his direct ownership position immediately following the 12,500-share open-market transaction.

Does Jerrold Grossman have indirect holdings of ADMA (ADMA) shares?

Yes. The Form 4 shows additional ADMA Biologics shares held indirectly through Brookwood LLC, the Jerrold Grossman 2019 Irrevocable Trust, Genesis Foundation Inc., and his wife, indicating related entities and family interests in ADMA stock.

What equity awards are included in Jerrold Grossman’s ADMA (ADMA) holdings?

His holdings include 10,690 restricted stock units (RSUs) granted on February 9, 2026. These RSUs will fully vest on February 9, 2027, provided he continues his service through that vesting date.